In recognition of Health Canada approval of the use ofHerceptin® for the treatment of metastatic breast cancer the Ministry of Health and Long-Term Care has provided funding for Herceptin® under the Provincial New Drug Program administered by Cancer Care Ontario. Fourteen laboratories throughout the province have been designated to provide the testing service for HER2/neu. An abnormal HER2/neu test result is the eligibility criteria for receiving Herceptin® treatment.

The laboratories that the ministry will fund to provide this regional testing service are as follows :

• Hamilton Health Sciences Corporation
• Kingston General Hospital
• Kitchener, Grand River Health Services
• London Health Sciences Centre
• Mississauga, Credit Valley Hospital
• North York General Hospital
• Oshawa, Lakeridge Health Corporation
• Ottawa Hospital Corporation
• Sudbury Regional Hospital
• Thunder Bay Regional Hospital
• Toronto, Mount Sinai Hospital
• Toronto, Sunnybrook and Women's College Health Sciences Centre
• Toronto, University Health Network
• Windsor Regional Hospital